CHMP puts Orexigen on first-to-market path in EU

Orexigen Therapeutics Inc. (NASDAQ: OREX) stands to be first to market with a new obesity drug in Europe as EMA's CHMP adopted a positive opinion for Mysimba naltrexone/ bupropion as an adjunct to reduced-calorie diet and increased physical activity for the management of weight in adults who are obese or are overweight with weight-related co-morbidities.

CHMP recommended treatment be stopped after 16 weeks if the patient has not lost at least 5% of initial body weight. ...